A three-month double-blind study of clobazam versus diazepam in out-patients suffering from neurotic disturbances.
Efficacy and safety of the 1,5 benzodiazepine, clobazam, in comparison to the 1,4 benzodiazepine, diazepam, were controlled in sixty psychiatric out-patients over a period of three months. In the course of this long treatment period data were obtained confirming findings of shorter-lasting studies. Global assessment of the therapeutic efficacy and the total scores of the Hamilton Anxiety Scale revealed no significant the compounds. Both groups showed a significant (p less than 0.01) improvement in the total scores of the Hamilton Anxiety Scale after two weeks of treatment. Scores of the individual items indicated distinct spectra of action: Clobazam was more effective in diminishing anxious mood, whereas diazepam was better able to influence muscular symptoms of anxiety. The relevance of the findings for a more individualized therapy is pointed out.
D000293:Adolescent; D000328:Adult; D014151:Anti-Anxiety Agents / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003975:Diazepam / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009497:Neurotic Disorders / Q000188:drug therapy*
D014151:Anti-Anxiety Agents; D003975:Diazepam